Why ARK Genomic Revolution ETF (ARKG) Is Down -10% in the Last 30 Days
Key Takeaways
- ARKG declined roughly 10% over the past 30 days, a pullback following a sharp year-to-date advance in genomics and biotechnology equities.
- The fund remains up approximately 27% over the past quarter and has nearly doubled from its 52-week low, underscoring the magnitude of its earlier rally.
- The recent slide reflects profit-taking and a rotation away from high-beta, small- and mid-cap growth names rather than a fundamental breakdown in the genomics theme.
- ARKG is an actively managed, non-diversified thematic ETF with effectively 100% of assets in healthcare, concentrating its risk in a narrow set of fast-growing companies.
- Top holdings such as Tempus AI (TEM), Twist Bioscience (TWST), 10x Genomics (TXG), and CRISPR Therapeutics (CRSP) account for a large share of the fund's daily volatility.
- For deeper analysis, explore additional Price Targets and Forecast pages to track ARKG's technical and predictive signals.
- Discover actionable ideas across the broader market by exploring Trending AI Robots.
ARK Genomic Revolution ETF (ARKG) Overview and Portfolio Exposure
ARKG is an actively managed exchange-traded fund (ETF) that invests at least 80% of its assets in domestic and foreign companies tied to the genomics revolution, spanning gene editing, DNA sequencing, bioinformatics, molecular diagnostics, and targeted therapeutics. The fund is non-diversified, meaning it can concentrate heavily in a relatively small number of positions, and it carries an expense ratio of 0.75%.
The portfolio holds roughly 30 to 35 stocks and is effectively 100% allocated to healthcare, with a small residual exposure to information technology. It is tilted toward small- and mid-cap companies with high growth expectations, which gives the fund an elevated beta relative to the broader market and annualized volatility historically in the low-to-mid 40% range.
Largest holdings include Tempus AI (TEM), Twist Bioscience (TWST), 10x Genomics (TXG), CRISPR Therapeutics (CRSP), Personalis (PSNL), Natera (NTRA), Illumina (ILMN), and CareDx (CDNA). This concentrated, growth-oriented structure amplifies both upside momentum and downside drawdowns, which helps explain the fund's recent whipsaw behavior.
ARK Genomic Revolution ETF (ARKG) Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ARKG fell from roughly $53.53 to about $48.16, a decline of approximately 10%. The move was not a smooth grind lower but a volatile, two-sided sequence: the fund spiked to around $56.77 before reversing sharply in a single session on unusually heavy volume, then slid toward $46.70 by mid-month before stabilizing.
Over the past quarter, the picture is materially different. From a level near $37.81 roughly three months earlier, the fund advanced roughly 27%, even after giving back a portion of its gains in October. This combination of a strong quarterly gain and a sharp recent pullback is characteristic of high-beta thematic funds that rally aggressively before consolidating.
What Drove ARKG Price in the Last 30 Days
The recent decline appears driven primarily by positioning and risk appetite rather than a specific deterioration in the genomics sector. After a powerful run that lifted ARKG to its 52-week high in early October, investors took profits in high-multiple, long-duration growth equities.
The fund's heaviest weights were central to the volatility. Tempus AI, Twist Bioscience, and 10x Genomics carry some of the largest positions in the portfolio, and their price swings translate directly into fund-level moves. Because ARKG holds many pre-profit, small- and mid-cap companies with valuations tied to future cash flows, the portfolio is acutely sensitive to interest-rate expectations and broader risk sentiment. A rise in volatility and a shift away from speculative growth coincided with the sell-off, while elevated trading volume around the reversal pointed to active repositioning.
What Drove ARKG Performance Over the Last Quarter
The quarter's gains reflected a broader resurgence in healthcare innovation and AI-enabled biotechnology. Companies such as Tempus AI and Recursion Pharmaceuticals (RXRX), which apply data and machine learning to drug discovery and diagnostics, benefited from renewed investor enthusiasm for precision medicine, while genomics platforms like Twist Bioscience and 10x Genomics rode improving sentiment across the tools and sequencing complex.
Supportive macroeconomic conditions, including moderating inflation and expectations for a more accommodative interest-rate path, favored long-duration growth stocks. Institutional and retail flows into thematic healthcare funds added momentum. The fund's concentrated structure meant that strength in a handful of large holdings disproportionately lifted overall returns, just as their subsequent pullback has weighed on recent performance.
AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. The tool is designed to surface trending securities, breakout candidates, and new opportunities more efficiently than manual screening. For investors monitoring thematic funds like ARKG, the screener can help identify which underlying holdings and peer stocks are showing the strongest relative momentum or shifting technical profiles. Explore the platform to refine your own research workflow and uncover actionable ideas across sectors and industries.
ARKG ETF Outlook: What Investors Should Watch Next
Several factors are likely to influence ARKG over the coming months. Interest-rate expectations and inflation trends remain central, given the portfolio's heavy weighting in long-duration growth companies whose valuations are sensitive to discount rates. Earnings and guidance from top holdings such as Tempus AI, Twist Bioscience, 10x Genomics, and Illumina will be key barometers of commercial execution and spending across the genomics ecosystem.
Regulatory and clinical developments, including FDA decisions and reimbursement dynamics for diagnostics and gene therapies, could act as catalysts or headwinds. Capital flows into thematic healthcare funds and overall risk appetite will also shape near-term price action. Investors should monitor concentration risk, high valuation multiples, and the fund's historically elevated volatility as persistent structural considerations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARKG's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ARKG turned positive on October 28, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in 47 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ARKG as a result. In 72 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
ARKG moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARKG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 22 of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 248 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 202 of 220 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARKG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 28 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health